Tirzepatide, marketed as Zepbound for weight management, has shown higher average weight loss than semaglutide in many trial comparisons
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Phase 3 trials will likely include more comprehensive metabolic panels, and it is possible that hormone endpoints will be added as exploratory outcomes
Clinical trials show average weight loss of 1520% of body weight with lifestyle changes
At Ocean Pacific Integrative Health Center, we can provide you with natural protocols to complement your medication to help you keep your weight loss goal with minimum side effects
Patients throughout Stamford, Fairfield County, lower Connecticut, and nearby areas can schedule an evaluation to determine whether GLP-1 weight loss treatment is appropriate